Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer

The purpose of this phase II randomised trial was to determine which of two schemes, raltitrexed-irinotecan or raltitrexed-oxaliplatin, offered better activity and less toxicity in patients with advanced colorectal cancer (CRC). A total of 94 patients with previously untreated metastatic CRC were in...

Descripción completa

Detalles Bibliográficos
Autores principales: Feliu, J, Castañón, C, Salud, A, Mel, J R, Escudero, P, Pelegrín, A, López-Gómez, L, Ruiz, M, González, E, Juárez, F, Lizón, J, Castro, J, González-Barón, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361515/
https://www.ncbi.nlm.nih.gov/pubmed/16265344
http://dx.doi.org/10.1038/sj.bjc.6602860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361515/
https://www.ncbi.nlm.nih.gov/pubmed/16265344
http://dx.doi.org/10.1038/sj.bjc.6602860

Ejemplares similares